1-(4-((3-Chloro-4-fluorocyclohexyl)amino)-7-methoxyquinazolin-6-yl)-5-hydroxypyrrolidin-2-one
- CAS
- 2190490-31-2
- Formula
- C19H16ClFN4O3
- MW
- 402.8 g/mol
VQ-035114
Impurity reference standards
Dacomitinib impurities & reference standards
Characterised Dacomitinib impurities, degradation products and related compounds for analytical method development, validation, QC release and regulatory filings.
6reference materials
COAHPLC · NMR · MS on request
Parent API: Dacomitinib
1110813-31-4 · C24H25ClFN5O2
N4-(3-Chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine
- CAS
- 179552-75-1
- Formula
- C15H12ClFN4O
- MW
- 318.73 g/mol
VQ-035446
FAQs — Dacomitinib impurities
Which Dacomitinib impurities do you supply?
We list 6 Dacomitinib-related reference materials, including process impurities, degradation products and related compounds. Each is supplied with a COA, and characterisation data (HPLC, 1H-NMR, MS, IR) can be provided on request.
What are Dacomitinib impurity standards used for?
They are used for analytical method development and validation, impurity identification and quantification, forced-degradation and stability studies, and to support ANDA, DMF and other regulatory submissions under ICH Q3A/Q3B (and ICH M7 for mutagenic impurities).
Can you synthesise a Dacomitinib impurity that is not listed?
Yes. Our custom synthesis service can prepare and characterise unlisted impurities, metabolites and labelled analogues from milligram to gram scale. Share the structure or name and required quantity for a quotation.
Request Dacomitinib impurity standards
We reply within one business day with price, pack options, lead time and documentation.